Mohammed S N, Smith P, Hodgson S V, Fentiman I S, Miles D W, Barnes D M, Millis R R, Rubens R D
Division of Medical and Molecular Genetics, Guy's Hospital, London, UK.
Br J Cancer. 1998 Jun;77(12):2252-6. doi: 10.1038/bjc.1998.374.
The clinicopathological characteristics of breast cancer in 95 women between the ages of 24 and 45 years with a family history of breast cancer were compared with tumours from 329 women with sporadic disease matched for age and year of diagnosis. There was a trend for the family history patients to have slightly smaller tumours (mean size 2.49 cm) than the controls (mean 3.04 cm) (Mann-Whitney test, P = 0.09). A significantly greater proportion of the familial cases had grade III infiltrating ductal carcinoma than did the controls (40% vs 27%; chi2(1) = 5.64, P = 0.02). Despite this, there were more cases of operable node-negative disease among the study group than among the controls (48% vs 32%; chi2(1) = 8.2, P = 0.004). There was a highly significant survival advantage for patients with a family history (chi2 = 22.4, P < 0.001). Five- and 10-year survival rates were 92% and 87% for those with a family history compared with 70% and 54% for those in the control group. This survival advantage was maintained when patients with operable disease only were considered. In multivariate analysis, which included age, tumour size, stage, histological grade and family history, family history was an independent predictor of favourable prognosis and, in a Cox model, was associated with a relative risk of survival of 6.11 (95% CI 2.81-13.28). These results suggest that familial breast cancer has a more favourable clinical course than the more common sporadic forms of the disease.
对95名年龄在24至45岁之间且有乳腺癌家族史的女性所患乳腺癌的临床病理特征,与329名年龄及诊断年份相匹配的散发性乳腺癌女性患者的肿瘤进行了比较。有家族史的患者肿瘤似乎略小于对照组(平均大小2.49厘米 vs 平均3.04厘米)(曼-惠特尼检验,P = 0.09)。家族性病例中III级浸润性导管癌的比例显著高于对照组(40% vs 27%;χ2(1)=5.64,P = 0.02)。尽管如此,研究组中可手术的无淋巴结转移疾病病例比对照组更多(48% vs 32%;χ2(1)=8.2,P = 0.004)。有家族史的患者有非常显著的生存优势(χ2 = 22.4,P < 0.001)。有家族史者的5年和10年生存率分别为92%和87%,而对照组分别为70%和54%。仅考虑可手术疾病患者时,这种生存优势依然存在。在包括年龄、肿瘤大小、分期、组织学分级和家族史的多变量分析中,家族史是预后良好的独立预测因素,在Cox模型中,与生存相对风险为6.11相关(95%可信区间2.81 - 13.28)。这些结果表明,家族性乳腺癌比更常见的散发性乳腺癌具有更有利的临床病程。